JP7141420B2 - 眼疾患を処置するためのオキシメタゾリン組成物および方法 - Google Patents

眼疾患を処置するためのオキシメタゾリン組成物および方法 Download PDF

Info

Publication number
JP7141420B2
JP7141420B2 JP2020045468A JP2020045468A JP7141420B2 JP 7141420 B2 JP7141420 B2 JP 7141420B2 JP 2020045468 A JP2020045468 A JP 2020045468A JP 2020045468 A JP2020045468 A JP 2020045468A JP 7141420 B2 JP7141420 B2 JP 7141420B2
Authority
JP
Japan
Prior art keywords
formulation
weight
aspects
administration
points
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020045468A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020183373A (ja
Inventor
デブリース ティナ
ジェイコブス デイビット
Original Assignee
アールブイエル ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アールブイエル ファーマシューティカルズ，インコーポレイテッド filed Critical アールブイエル ファーマシューティカルズ，インコーポレイテッド
Publication of JP2020183373A publication Critical patent/JP2020183373A/ja
Priority to JP2021155526A priority Critical patent/JP7705326B2/ja
Application granted granted Critical
Publication of JP7141420B2 publication Critical patent/JP7141420B2/ja
Priority to JP2025014721A priority patent/JP2025065198A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10—Bag-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2020045468A 2019-05-06 2020-03-16 眼疾患を処置するためのオキシメタゾリン組成物および方法 Active JP7141420B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021155526A JP7705326B2 (ja) 2019-05-06 2021-09-24 眼疾患を処置するためのオキシメタゾリン組成物および方法
JP2025014721A JP2025065198A (ja) 2019-05-06 2025-01-31 眼疾患を処置するためのオキシメタゾリン組成物および方法

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962843819P 2019-05-06 2019-05-06
US201962844069P 2019-05-06 2019-05-06
US62/844,069 2019-05-06
US62/843,819 2019-05-06
US16/716,014 US10799481B1 (en) 2019-05-06 2019-12-16 Compositions and methods for treating ocular disorders
US16/715,998 US10814001B1 (en) 2019-05-06 2019-12-16 Oxymetazoline compositions
US16/716,014 2019-12-16
US16/715,998 2019-12-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021155526A Division JP7705326B2 (ja) 2019-05-06 2021-09-24 眼疾患を処置するためのオキシメタゾリン組成物および方法

Publications (2)

Publication Number Publication Date
JP2020183373A JP2020183373A (ja) 2020-11-12
JP7141420B2 true JP7141420B2 (ja) 2022-09-22

Family

ID=72750169

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020045468A Active JP7141420B2 (ja) 2019-05-06 2020-03-16 眼疾患を処置するためのオキシメタゾリン組成物および方法
JP2021155526A Active JP7705326B2 (ja) 2019-05-06 2021-09-24 眼疾患を処置するためのオキシメタゾリン組成物および方法
JP2025014721A Pending JP2025065198A (ja) 2019-05-06 2025-01-31 眼疾患を処置するためのオキシメタゾリン組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021155526A Active JP7705326B2 (ja) 2019-05-06 2021-09-24 眼疾患を処置するためのオキシメタゾリン組成物および方法
JP2025014721A Pending JP2025065198A (ja) 2019-05-06 2025-01-31 眼疾患を処置するためのオキシメタゾリン組成物および方法

Country Status (17)

Country Link
US (11) US10814001B1 (enExample)
EP (1) EP3965737A1 (enExample)
JP (3) JP7141420B2 (enExample)
KR (3) KR102410503B1 (enExample)
CN (2) CN111888326B (enExample)
AU (1) AU2020268329A1 (enExample)
BR (1) BR112021022404A2 (enExample)
CA (1) CA3139443A1 (enExample)
CL (1) CL2021002918A1 (enExample)
CO (1) CO2021015265A2 (enExample)
IL (1) IL287831A (enExample)
MA (1) MA55895A (enExample)
MX (1) MX2021013516A (enExample)
PE (1) PE20220384A1 (enExample)
SG (1) SG11202112272TA (enExample)
WO (1) WO2020227260A1 (enExample)
ZA (2) ZA202108950B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225918A1 (en) * 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
US10814001B1 (en) * 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions
US20240156786A1 (en) 2021-03-03 2024-05-16 Voom, Llc Compositions and methods for treatment of blepharitis
WO2023079427A1 (en) * 2021-11-03 2023-05-11 Avaca Pharma Private Limited Ophthalmic compositions and methods thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014506927A (ja) 2011-03-03 2014-03-20 ブーム・リミテッド・ライアビリティ・カンパニー 眼瞼下垂症の非外科的治療用組成物および方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE51421B1 (en) 1980-08-01 1986-12-24 Smith & Nephew Ass Ophthalmic compositions containing triamterene
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
US5888493A (en) 1996-12-05 1999-03-30 Sawaya; Assad S. Ophthalmic aqueous gel formulation and related methods
DE10337186A1 (de) * 2003-08-13 2005-03-17 Merck Patent Gmbh Wässrige Wirkstoff-Lösung
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
JP2006131628A (ja) * 2004-10-08 2006-05-25 Rohto Pharmaceut Co Ltd オキシメタゾリン含有水性組成物
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
TWI454286B (zh) 2006-03-17 2014-10-01 Johnson & Johnson Vision Care 安定氧化性不安定組合物之方法
CA2650592A1 (en) 2006-04-26 2007-11-08 Aciex, Inc. Compositions for the treatment and prevention of eyelid swelling
US8466203B2 (en) * 2006-12-06 2013-06-18 David Choohyun Paik Method of stabilizing human eye tissue by reaction with nitrite and related agents such as nitro compounds
MX2010006932A (es) * 2007-12-21 2010-10-05 Schering Plough Healthcare Aumento de la fotoestabilizacion de la oximetazolina.
CA2717605C (en) * 2008-03-11 2012-05-15 Alcon Research Ltd. Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
CA2764477A1 (en) * 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations, methods of manufacture, and methods of using same
US20120082625A1 (en) 2010-09-28 2012-04-05 Michael Graeber Combination treatment for rosacea
WO2012063237A2 (en) * 2010-11-08 2012-05-18 Healor Ltd. Buffered ophthalmic compositions and methods of use thereof
CA2819633C (en) 2010-12-03 2019-04-23 Allergan, Inc. Pharmaceutical cream compositions and methods of use
JP2015518006A (ja) 2012-05-25 2015-06-25 エクスクリア インコーポレイテッド キシリトール系の抗粘膜組成物及び関連する方法並びに組成物
UA119324C2 (uk) 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
WO2015040086A1 (en) 2013-09-18 2015-03-26 Mycronic AB Method, system and device for handling pallets in an smt system
WO2015191917A1 (en) 2014-06-11 2015-12-17 Allergan, Inc. Stabilized oxymetazoline formulations and their uses
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
US20170312335A1 (en) * 2015-12-30 2017-11-02 Lubris Llc Topical use of prg4 for treatment of allergy and symptoms of inflammation
CN115006537A (zh) 2016-01-26 2022-09-06 利维申制药有限公司 α-肾上腺素能药剂的组合物和用途
CN105997856A (zh) * 2016-06-24 2016-10-12 魏威 盐酸羟甲唑啉滴眼液及其制备方法
US11246816B2 (en) 2016-06-30 2022-02-15 The Procter And Gamble Company Shampoo compositions comprising a chelant
US10814001B1 (en) 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014506927A (ja) 2011-03-03 2014-03-20 ブーム・リミテッド・ライアビリティ・カンパニー 眼瞼下垂症の非外科的治療用組成物および方法

Also Published As

Publication number Publication date
US11311515B2 (en) 2022-04-26
CN117045596A (zh) 2023-11-14
US20210137889A1 (en) 2021-05-13
US20200353083A1 (en) 2020-11-12
KR102410503B1 (ko) 2022-06-17
JP2020183373A (ja) 2020-11-12
US20240033250A1 (en) 2024-02-01
US20220273621A1 (en) 2022-09-01
MA55895A (fr) 2022-03-16
US11701343B2 (en) 2023-07-18
AU2020268329A1 (en) 2022-01-06
CA3139443A1 (en) 2020-11-12
KR20220084264A (ko) 2022-06-21
US11103482B2 (en) 2021-08-31
PE20220384A1 (es) 2022-03-18
US10898573B1 (en) 2021-01-26
CO2021015265A2 (es) 2022-02-28
US20230355587A1 (en) 2023-11-09
CL2021002918A1 (es) 2022-08-19
MX2021013516A (es) 2022-01-24
ZA202108950B (en) 2023-10-25
JP2021191802A (ja) 2021-12-16
US11541036B2 (en) 2023-01-03
US10799481B1 (en) 2020-10-13
US20210015795A1 (en) 2021-01-21
NZ782902A (en) 2024-09-27
JP2025065198A (ja) 2025-04-17
US20220257566A1 (en) 2022-08-18
ZA202212328B (en) 2025-03-26
US10814001B1 (en) 2020-10-27
SG11202112272TA (en) 2021-12-30
US20210212992A1 (en) 2021-07-15
CN111888326A (zh) 2020-11-06
WO2020227260A1 (en) 2020-11-12
BR112021022404A2 (pt) 2022-01-18
IL287831A (en) 2022-01-01
JP7705326B2 (ja) 2025-07-09
US20210023222A1 (en) 2021-01-28
KR20200128629A (ko) 2020-11-16
US20210386711A1 (en) 2021-12-16
US10940138B2 (en) 2021-03-09
KR102663319B1 (ko) 2024-05-03
US11324722B2 (en) 2022-05-10
CN111888326B (zh) 2023-07-21
EP3965737A1 (en) 2022-03-16
KR20240060580A (ko) 2024-05-08
KR102859351B1 (ko) 2025-09-12

Similar Documents

Publication Publication Date Title
KR102859351B1 (ko) 안구 장애를 치료하기 위한 옥시메타졸린 조성물 및 방법
EP3463360B1 (en) Atropine-containing aqueous composition
AU2018371787A1 (en) Ophthalmic composition and delivery device thereof
RU2820596C2 (ru) Композиции оксиметазолина и способы для лечения офтальмологических расстройств
HK40031931A (en) Oxymetazoline compositions and methods for treating ocular disorders
HK40031931B (zh) 羟甲唑啉组合物和用於治疗眼障碍的方法
BR122024023871A2 (pt) Formulações livres de conservantes oftálmicas aquosas farmaceuticamente estáveis, recipientes de uso único, bem como usos terapêuticos das ditas formulações
EA044560B1 (ru) Водная композиция, содержащая атропин
HK40004290B (en) Atropine-containing aqueous composition
HK40004290A (en) Atropine-containing aqueous composition

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220513

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220815

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220909

R150 Certificate of patent or registration of utility model

Ref document number: 7141420

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250